Parkinson's disease is a neurodegenerative disorder affecting the central nervous system, leading to symptoms like muscle rigidity, tremors, and loss of balance and coordination.
We offer the latest therapeutic technologies for Parkinson's disease, focusing on slowing disease progression and significantly improving patients' motor functions.
New Pharmacotherapies:
New drugs have been developed to reduce the "off-time" between doses of traditional medications like Carbidopa/Levodopa, ensuring better symptom control throughout the day.
Cellular Therapies:
Cellular therapies are a major advancement, involving the transplantation of dopamine-producing cells (like Bemdaneprocel, BRT-DA01) into the brain to replace damaged neurons. Clinical studies have shown this treatment to be safe and effective in improving motor functions.
Inhibition of Protein Aggregates:
We use AI to accelerate the discovery of drugs that prevent the aggregation of alpha-synuclein protein, a hallmark of Parkinson's, helping to slow disease progression.
Reducing Inflammation:
Some new drugs work by reducing inflammation in the brain by targeting specific compounds like the NLRP3 inflammasome, which helps protect neurons.
Inhibition of Apoptosis:
New drugs like KM-819 are being developed to target apoptosis (programmed cell death) to protect neurons from dying, thereby slowing the progression of the disease.
Key Features
Cellular Therapies
Transplanting dopamine-producing cells into the brain to replace damaged neurons and improve movement.
Protein Aggregate Inhibition
Using innovative drugs to prevent the aggregation of harmful alpha-synuclein protein to slow disease progression.
Reducing Brain Inflammation
New drugs that target the reduction of inflammation in the brain to protect neurons from damage.
Apoptosis Inhibition
Modern treatments aimed at protecting neurons from programmed cell death to slow the course of the disease.